HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. ORIC | 0.00 |
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:
ORIC) with a Buy and maintains $25 price target.
